FDA Extends Trikafta Approval to Even Younger Cystic Fibrosis Patients

(MedPage Today) -- The FDA expanded the indication for elexacaftor, tezacaftor, and ivacaftor (Trikafta) in cystic fibrosis to include even younger children, maker Vertex Pharmaceuticals announced. The three-drug combination's expanded label now...
Source: MedPage Today Pediatrics - Category: Pediatrics Source Type: news